Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Outcomes of Children With BCR-ABL1 –Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease

Open access
Roberts, Kathryn G., Pei, Deqing, Campana, Dario, Payne-Turner, Debbie, Li, Yongjin, Cheng, Cheng, Sandlund, John T., Jeha, Sima, Easton, John, Becksfort, Jared, Zhang, Jinghui, Coustan-Smith, Elaine, Raimondi, Susana C., Leung, Wing H., Relling, Mary V., Evans, William E., Downing, James R., Mullighan, Charles G., Pui, Ching-Hon·2014·Journal of Clinical Oncology

Abstract

Purpose: BCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL) subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1–like ALL treated with risk-directed therapy based on minimal residual disease (MRD) levels during remission induction. Patients and Methods: Among 422 patients with B-ALL enrolled onto the Total Therapy XV study between 2000 and 2007, 344 had adequate samples for gene expression profiling. Next-generation sequencing and/or analysis of genes known to be altered in B-ALL were performed in patients with BCR-ABL1–like ALL who had available material. Outcome was compared between patients with and those without BCR-ABL1–like ALL. Results: Forty (11.6%) of the 344 patients had BCR-ABL1–like ALL. They were significantly more likely to be male, have Down syndrome, and have higher MRD levels on day 19 and at the end of induction than did other patients with B-ALL. Among 25 patients comprehensively studied for genetic abnormalities, 11 harbored a genomic rearrangement of CRLF2, six had fusion transcripts responsive to ABL tyrosine kinase inhibitors or JAK inhibitors, and seven had mutations involving the Ras signaling pathway. There were no significant differences in event-free survival (90.0% ± 4.7% [SE] v 88.4% ± 1.9% at 5 years; P = .41) or in overall survival (92.5% ± 4.2% v 95.1% ± 1.3% at 5 years; P = .41) between patients with and without BCR-ABL1–like ALL. Conclusion: Patients who have BCR-ABL1–like ALL with poor initial treatment response can be salvaged with MRD-based risk-directed therapy and may benefit from identification of kinase-activating lesions for targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.55.4105

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 256

Metadata

Authors
Roberts, K. G., Pei, D., Campana, D., Payne-Turner, D., Li, Y., Cheng, C., Sandlund, J. T., Jeha, S., Easton, J., Becksfort, J., Zhang, J., Coustan-Smith, E., Raimondi, S. C., Leung, W. H., Relling, M. V., Evans, W. E., Downing, J. R., Mullighan, C. G., & Pui, C.-H.
Venue
Journal of Clinical Oncology
Published
2014-09-20
Volume
32
Issue
27
Pages
3012-3020
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2075043727
Cited by
256
References
36
FWCI
29.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of Children With BCR-ABL1 –Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease. https://app.cochat.ai/papers/10.1200/jco.2014.55.4105
The paper
Roberts, K. G., Pei, D., Campana, D., Payne-Turner, D., Li, Y., Cheng, C., Sandlund, J. T., Jeha, S., Easton, J., Becksfort, J., Zhang, J., Coustan-Smith, E., Raimondi, S. C., Leung, W. H., Relling, M. V., Evans, W. E., Downing, J. R., Mullighan, C. G., & Pui, C.-H. (2014). Outcomes of Children With BCR-ABL1 –Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.55.4105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.